EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as Novel Predictive Biomarkers for Ramucirumab–Paclitaxel Therapy Outcomes in Advanced Gastric Cancer

Emanuele Piccinno iD, Annalisa Schirizzi, Viviana Scalavino iD, Giampiero De Leonardis, Rossella Donghia iD, Alessia Fantasia, Angela Dalia Ricci, Claudio Lotesoriere iD, Gianluigi Giannelli iD, Grazia Serino iD, Rosalba D'Alessandro iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252413498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Emanuele Piccinno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Medicine, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grott…. Hauptthemen laut MEDLINE: Stomach Neoplasms, MicroRNAs, Ramucirumab, Paclitaxel. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Public Health, Italian Ministry of Public Health [Ricerca Corrente 2024].

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiogenesis inhibition treatments are limited and are often too late for advanced gastric cancer (GC) patients, in whom its efficacy is reduced. New molecular biomarkers are needed to optimize therapy regimens. In regard to this framework, circulating miRNAs, with high sensitivity and specificity, could be useful biomarkers of GC. The present longitudinal study was focused on analyzing the expression levels of a blood miRNA signature in a cohort of 40 patients receiving second-line therapy combining Ramucirumab and Paclitaxel, stratified based on their Progression-Free Survival (PFS). Using differential and bioinformatic analysis, miR-205-5p, miR-30e-3p, and miR-23b-3p were selected as possible predictive biomarkers, with the results showing that they were more highly expressed in patients exhibiting longer PFS and that they were involved in modulating angiogenesis. Furthermore, patients with longer PFS showed a progressive and significant decrease in the selected miRNA to minimal levels. The loss of the protective effect and the increased expression of the hypothetical targets, including angiopoietin-2, were then observed. The hypothesis was supported by the inverse correlation found for miR-205-5p and angiopoietin-2. Circulating levels of miR-205-5p were protective (HR = 0.37, p = 0.02) and patients with higher baseline miRNA levels had longer OS (12.47 vs. 9.00 months). Our findings suggest that these three miRNAs may be novel candidates as non-invasive predictive markers of therapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsMicroRNAsRamucirumabPaclitaxelAntibodies, Monoclonal, HumanizedBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedCirculating MicroRNAGene Expression Regulation, NeoplasticTreatment OutcomeAdultPrognosisAngiopoietin-2

Stichwörter der Autor:innen

advanced gastric cancerangiogenesisbiomarkerscirculating miRNAs

Substanzen

MicroRNAsRamucirumabPaclitaxelAntibodies, Monoclonal, HumanizedBiomarkers, TumorMIRN23a microRNA, humanCirculating MicroRNAMIRN30a microRNA, humanMIRN30b microRNA, humanAngiopoietin-2

Autor:innen und Institutionen

  • Laboratory of Molecular Medicine, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, BA, Italy.
  • Laboratory of Experimental Oncology, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, BA, Italy.
  • Data Science Unit, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, BA, Italy.
  • Clinical Trial Unit, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, BA, Italy.
  • Medical Oncology Unit, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, BA, Italy.
  • Scientific Direction, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, BA, Italy.

ORCID-Profile: Emanuele Piccinno, Viviana Scalavino, Rossella Donghia, Claudio Lotesoriere, Gianluigi Giannelli, Grazia Serino, Rosalba D'Alessandro

Förderung

  • Italian Ministry of Public Health
  • Italian Ministry of Public Health [Ricerca Corrente 2024]

Zitieren

APA

Piccinno, E., Schirizzi, A., Scalavino, V., De Leonardis, G., Donghia, R., Fantasia, A., Ricci, A. D., Lotesoriere, C., Giannelli, G., Serino, G., & D'Alessandro, R. (2024). Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as Novel Predictive Biomarkers for Ramucirumab–Paclitaxel Therapy Outcomes in Advanced Gastric Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413498

Vancouver

Piccinno E, Schirizzi A, Scalavino V, De Leonardis G, Donghia R, Fantasia A, et al. Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as Novel Predictive Biomarkers for Ramucirumab–Paclitaxel Therapy Outcomes in Advanced Gastric Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413498

BibTeX
@article{Piccinno2024,
  author = {Piccinno, Emanuele and Schirizzi, Annalisa and Scalavino, Viviana and De Leonardis, Giampiero and Donghia, Rossella and Fantasia, Alessia and Ricci, Angela Dalia and Lotesoriere, Claudio and Giannelli, Gianluigi and Serino, Grazia and D'Alessandro, Rosalba},
  title = {Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as Novel Predictive Biomarkers for Ramucirumab–Paclitaxel Therapy Outcomes in Advanced Gastric Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252413498}
}
Kostenlos starten →